WO2011118604A1 - Timbre transdermique adhésif hydraté - Google Patents

Timbre transdermique adhésif hydraté Download PDF

Info

Publication number
WO2011118604A1
WO2011118604A1 PCT/JP2011/056896 JP2011056896W WO2011118604A1 WO 2011118604 A1 WO2011118604 A1 WO 2011118604A1 JP 2011056896 W JP2011056896 W JP 2011056896W WO 2011118604 A1 WO2011118604 A1 WO 2011118604A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesive layer
water
mass
sensitive adhesive
pressure
Prior art date
Application number
PCT/JP2011/056896
Other languages
English (en)
Japanese (ja)
Inventor
尚久 川村
Original Assignee
ニプロパッチ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニプロパッチ株式会社 filed Critical ニプロパッチ株式会社
Priority to JP2012507022A priority Critical patent/JPWO2011118604A1/ja
Publication of WO2011118604A1 publication Critical patent/WO2011118604A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the present invention relates to a water-containing patch containing a drug.
  • a drug is transdermally absorbed with a water-containing patch for the purpose of sustained release of the drug or local supply.
  • lidocaine is known to be capable of functioning as a pain relief agent for persistent pain such as herpes zoster or postherpetic neuralgia, a local anesthetic, etc.
  • absorption by a transdermal route is more appropriate than an administration route such as oral or injection, and a patch is attracting attention (Patent Document 1).
  • the conventional adhesive has a great deal of pain when peeled off from the skin after use because the adhesive strength becomes too strong with time after application to the skin.
  • pain when peeling the patch is a very important problem.
  • the patch needs to be applied to the affected area for a long time, especially in the case of persistent pain such as herpes zoster or postherpetic neuralgia, because it is often applied to frequently moving places such as joints, The movement may cause a part of the patch to peel off.
  • the conventional patch has a problem that it is difficult to re-stick to the skin in such a case.
  • the present invention has been made in view of the above circumstances, and provides a water-containing patch that contains a drug such as lidocaine, reduces the pain given to the user at the time of peeling, and has excellent re-sticking power. With the goal.
  • the inventor suppresses the blending amount of water to 30% by mass or less with respect to the total mass of the pressure-sensitive adhesive layer, and adds 40% by mass or more of polyhydric alcohol to the total mass of the pressure-sensitive adhesive layer. It was found that the re-sticking force was improved while the increase in the adhesive force was moderately suppressed by blending into the present invention, and the present invention was completed. Specifically, the present invention provides the following.
  • a hydrous patch comprising a support and a pressure-sensitive adhesive layer located on the support, In the pressure-sensitive adhesive layer, a drug, water in an amount of 30% by mass or less with respect to the total mass of the pressure-sensitive adhesive layer, and a polyhydric alcohol in an amount of 40% by mass or more with respect to the total mass of the pressure-sensitive adhesive layer;
  • a water-containing patch comprising
  • the pressure-sensitive adhesive layer includes water in an amount of 30% by mass or less with respect to the total mass of the pressure-sensitive adhesive layer, and polyhydric alcohol in an amount of 40% by mass or more with respect to the total mass of the pressure-sensitive adhesive layer. Therefore, the resticking force can be improved while suppressing an increase in adhesive strength so that the pain given to the user at the time of peeling is reduced.
  • the hydrous patch according to the present invention comprises a support and an adhesive layer located on the support and containing a drug. Details of each element will be described below.
  • the pressure-sensitive adhesive layer has water in an amount of 30% by mass or less with respect to the total mass of the pressure-sensitive adhesive layer and a polyvalent amount in an amount of 40% by mass or more with respect to the total mass of the pressure-sensitive adhesive layer. And alcohol. Thereby, the re-sticking force can be improved while suppressing an increase in adhesive force.
  • the amount of water may be appropriately selected from the range of 30% by mass or less, more preferably 28% by mass or less, as long as it is acceptable in the production of the preparation. If the lower limit of the amount of water is too small, the amount of other components (for example, glycerin and the like) increases, and the manufacturing cost increases, and a sufficient amount of other components (for example, polyacrylic acid and / or its components). In view of the fact that the salt is not dissolved, it may be appropriately set. In general, it is preferably 10% by mass, more preferably 15% by mass with respect to the total mass of the pressure-sensitive adhesive layer.
  • the blending amount of the polyhydric alcohol may be appropriately selected from the above range, but it is 40 masses with respect to the total mass of the pressure-sensitive adhesive layer from the viewpoint of further suppressing the increase in the adhesive force and improving the excellent re-adhesion force. % Or more, and more preferably 50% by mass or more.
  • the upper limit of the blending amount of the polyhydric alcohol may be appropriately set in consideration of the blending amount of water, manufacturing cost, ease of bleeding, and the like.
  • polyhydric alcohol examples include glycerin, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,3-propanediol, 1,3-butanediol, 1,4-butanediol, Examples include 1,2,6-hexanetriol, maltitol, and xylitol. These may be used alone or in combination of two or more, and among them, glycerin is preferably contained.
  • the glycerin includes concentrated glycerin (glycerin content: 98.0 to 101.0%) and other glycerin (glycerin content: 84 to 87%), and is not particularly limited. 101.0%) is more preferable.
  • the drug is not particularly limited and may be any drug.
  • topical anesthetics and various kinds of drugs are particularly suitable for use in the treatment or prevention of neuralgia because the hydrous patch of the present invention is particularly required.
  • Analgesics Specifically, local anesthetics such as tetracaine, procaine, dibucaine, lidocaine, benzocaine, mexiletine, ropivacaine, and pharmaceutically acceptable salts thereof, indomethacin, ketoprofen, piroxicam, felbinac, bufexamac, suprofen, flurubi
  • Non-steroidal anti-inflammatory drugs such as profen, diclofenac, ibuprofen, loxoprofen, ampenac and their pharmaceutically acceptable salts
  • antidepressants such as amitriptin
  • anticonvulsants such as gabapentin
  • steroids such as prednisolone
  • capsaicin Other analgesics such as acetamin
  • Lidocaine is a useful drug as listed in the Japanese Pharmacopoeia as a relief agent for persistent pain such as herpes zoster or postherpetic neuralgia, a local anesthetic, and an antiarrhythmic drug.
  • Lidocaine contained in the pressure-sensitive adhesive layer is mainly in a free form, but may be in the form of a pharmacologically acceptable salt.
  • the pharmacologically acceptable salt is not particularly limited, but is preferably a hydrochloride.
  • the compounding amount of lidocaine and / or a pharmacologically acceptable salt thereof (hereinafter also referred to as lidocaine) is not particularly limited, but if it is too much, lidocaine precipitates vigorously and is difficult to maintain in the preparation. On the other hand, if the amount is too small, it is difficult to obtain a sufficient effect. Therefore, the amount of lidocaine is 0.1 to 50% by weight, preferably 1.0 to 30% by weight, more preferably 3 to 10% by weight, based on the total weight of the pressure-sensitive adhesive layer. Most preferably, it is 5 mass%.
  • the pressure-sensitive adhesive layer is made of an inorganic powder, a surfactant, an excipient such as N-methyl-2-pyrrolidone, polyacrylic acid and / or a salt thereof, a cross-linking agent, a cross-linking agent, if necessary. It may contain optional components such as a control agent, an adhesion enhancer, a lidocaine dissolution aid, a pH adjuster, a cooling agent, a water-soluble polymer compound, an inorganic powder, an antioxidant, a preservative, and a pigment.
  • the inorganic powder examples include kaolin, zinc oxide, titanium oxide, anhydrous silicic acid, light anhydrous silicic acid and the like, and these may be included singly or in combination of two or more. Inorganic powder suppresses an excessive increase in adhesive strength. Therefore, the blending amount of the inorganic powder is preferably such that the sum of the blending amount of the polyhydric alcohol is 50% by mass or more with respect to the total mass of the pressure-sensitive adhesive layer.
  • the adhesive layer contains the predetermined amount of water and a polyhydric alcohol, thereby exhibiting effects such as suppression of increase in adhesive force.
  • the adhesive layer may contain a surfactant or the like, but even if it does not contain it, the water-containing patch has excellent suppression of an increase in adhesive force.
  • the surfactant is not particularly limited, Sorbitan fatty acid esters such as sorbitan sesquioleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, glyceryl fatty acid esters such as glyceryl monostearate, polyglycerin fatty acid esters such as hexaglyceryl monolaurate, decaglyceryl dekaoleate, Polyethylene glycol fatty acid esters such as polyethylene glycol distearate, polyethylene glycol monostearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitol tetraoleate Polyoxyethylene sorbite fatty acid ester, monooleic acid polyoxy Polyoxyethylene glyceryl fatty acid esters such as ethylene glyceryl, polyoxyethylene alkyl ethers such as polyoxyethylene
  • the pH of the pressure-sensitive adhesive layer is preferably adjusted to 4.5 to 9, more preferably 6 to 7.4. If it is less than 4.5, the transfer of a drug, particularly lidocaine, to the skin is deteriorated. Therefore, the pH of the pressure-sensitive adhesive layer is desired to be 4.5 or more, but in such a weakly acidic pH range, it is different from a commonly used crosslinking agent, specifically dihydroxyaluminum aminoacetate (also known as Aluminum glycinate) is preferably used.
  • Aluminum of dihydroxyaluminum aminoacetate elutes well from weak acidity to near neutrality, and can cross-link well with polyacrylic acid (salt) and the like described later.
  • the cross-linking agent is not limited to dihydroxyaluminum aminoacetate, and examples thereof include polyvalent metal salts.
  • aluminum compounds are preferable.
  • the aluminum compound include hydroxides such as dihydroxyaluminum aminoacetate, aluminum hydroxide, and aluminum hydroxide gel described above, or salts of inorganic or organic acids such as aluminum chloride, aluminum sulfate, aluminum acetate, and aluminum stearate.
  • double salts such as aluminum alum, aluminates such as sodium aluminate, inorganic aluminum complex salts, and organic aluminum chelate compounds.
  • These aluminum compounds may be water-soluble or sparingly soluble.
  • the pH can be set using a pH adjuster, such as tartaric acid, phosphoric acid, malic acid, citric acid, hydrochloric acid, sodium hydroxide, triethanolamine, diethanolamine, diisopropanolamine, etc. These may be included singly or in combination of two or more, but tartaric acid and phosphoric acid are preferred.
  • a pH adjuster such as tartaric acid, phosphoric acid, malic acid, citric acid, hydrochloric acid, sodium hydroxide, triethanolamine, diethanolamine, diisopropanolamine, etc.
  • polyacrylic acid and / or salts thereof examples include polyacrylic acid, sodium polyacrylate, and partially neutralized polyacrylic acid “NP-800 (trade name)” and “NP-700 (trade name)” (Showa Denko) These may be included singly or in combination of two or more.
  • adhesion enhancer examples include methacrylic acid / n-butyl acrylate copolymer, methyl acrylate / 2-ethylhexyl acrylate copolymer, polybutene, ester gum, terpene resin, alicyclic saturated hydrocarbon resin, and the like.
  • the blending amount thereof may be 1% by mass or more and 30% by mass or less, and preferably 5% by mass or more and 20% by mass or less, based on the total mass of the pressure-sensitive adhesive layer.
  • crosslinking control agent examples include sodium edetate (disodium ethylenediaminetetraacetate), citric acid and the like, and these may be used alone or in combination of two or more, but sodium edetate is preferred.
  • lidocaine solubilizers include crotamiton, N-methyl-2-pyrrolidone, mint oil, 1,3-butylene glycol, etc., and these may be used alone or in combination of two or more. It's okay.
  • Examples of the refreshing agent include camphor and thymol, l-menthol, dl-menthol, 2-methyl-3- (l-menthyloxy) propane-1,2-diol, 3-l-mentoxypropane-1, Examples include menthol derivatives such as 2-diol and 5-methyl-2- (l-methylethyl) -cyclohexyl-2-hydroxypropionate, and these may be included singly or in combination of two or more. .
  • water-soluble polymer compounds include gelatin, agar, polyvinyl alcohol, polyvinyl pyrrolidone, propylene carbonate, carboxymethyl cellulose, carboxymethyl cellulose sodium, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, sodium alginate, maleic anhydride copolymer. , Carrageenan and the like, and these may be included singly or in combination of two or more.
  • antioxidants examples include tocopherol acetate, ascorbic acid and / or derivatives thereof, sodium sulfite, sodium hydrogen sulfite, sodium pyrosulfite, sodium nitrite, dibutylhydroxytoluene and the like. These may be used alone or in combination of two or more. May be included in combination.
  • preservative examples include methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, thymol, and the like, and these may be used alone or in combination of two or more.
  • the type of the dye is not particularly limited, and examples thereof include dyes described in the Legal Dye Handbook, and these can be used alone or in combination of two or more.
  • the support may be composed of fabrics such as woven fabrics, nonwoven fabrics, and knitted fabrics that are conventionally used for patches, resin films, paper, and laminates thereof.
  • the material of the support may be one or more selected from the group consisting of polypropylene, polyethylene, polybutylene, polyethylene terephthalate, rayon, cotton, and polyurethane, and is not particularly limited, but is preferably polyethylene terephthalate. From the viewpoint of cost, a support composed of a nonwoven fabric made of polyethylene terephthalate is preferably used.
  • the patch according to the present invention may further include a release liner that covers the pressure-sensitive adhesive layer.
  • a release liner a resin film such as polyethylene terephthalate or polypropylene is preferable, and a release film such as silicon or an embossed film may be used.
  • what printed or kneaded paints, such as white, can also be used as a peeling liner.
  • the above patches can be used for any purpose depending mainly on the drug to be blended.
  • particularly useful uses include the treatment or prevention of persistent pain such as herpes zoster or postherpetic neuralgia. Since the patch of the present invention suppresses an increase in adhesive force, the pain given to the user at the time of peeling is reduced, and the adhesive is kept applied for a long time, and has an excellent re-adhesion power. Re-sticking can be performed.
  • the patch of the present invention can be prepared by a conventional method, and the above-mentioned essential components and, if necessary, the above optional components are appropriately blended and kneaded until uniform by a known method. After spreading on the release liner so that the pressure-sensitive adhesive mass at 0.03 to 0.15 g / cm 2 , a support was further laminated on the surface of the pressure-sensitive adhesive layer, and then cut into a 100 mm ⁇ 140 mm rectangular shape Can be prepared. It can also be prepared by first spreading a pressure-sensitive adhesive on a support and then laminating a release liner thereon.
  • Examples 1 to 11 and Comparative Examples 1 to 3 For Examples and Comparative Examples, the components shown in Tables 1 to 3 were stirred and mixed for a certain period of time, and then the adhesive mass per patch (140 mm ⁇ 100 mm) was about 14 g on the release liner. It was spread evenly. Thereafter, a nonwoven fabric made of polyethylene terephthalate was bonded to the surface of the pressure-sensitive adhesive layer, and then cut into a size of 100 mm ⁇ 140 mm to prepare a patch. The amounts shown in Tables 1 to 3 are all mass%.
  • Test Example 1 Adhesiveness to skin The patches of each Example and Comparative Example were cut into 2.0 ⁇ 3.0 cm and attached to the human forearm. After 8 hours, using "Sun Rheo Meter CR-200D" (manufactured by Sun Scientific Co, Ltd.), the patch was applied to the skin at a speed of 300 mm / min according to the test method of JIS Z0237. The peel force when peeled in the direction was measured.
  • Examples 1 to 11 had lower adhesive strength than Comparative Examples 1 to 3, while having necessary adhesive strength of 41.5 g / 2.5 cm or more. In fact, none of the patches of Examples 1 to 11 were naturally peeled off from the skin during the application for 8 hours.
  • Test Example 2 Pain at the time of peeling In Test Example 1, the degree of pain at the time of peeling from the human forearm after 8 hours was subjected to sensory evaluation by eight monitors. The evaluation criteria are as follows. A: There is no pain at all. ⁇ : I do not feel pain. ⁇ : Somewhat strong pain is felt, and the skin is pulled. X: A strong pain is felt and accompanied by pain.
  • Test Example 3 Re-sticking power to the skin The patch after 8 hours had been peeled off from the skin and then applied to the skin again. Thereafter, the peel force was measured in the same procedure as in Test Example 1.
  • Example 12 to 13 A patch was prepared in the same procedure as in Example 1 except that each component shown in Table 4 was blended.
  • Lidocaine Skin Permeability 0.05 mol / L McIlvaine buffer (pH 7.4) is 1 in the receiver on the dermis layer side of hairless mouse-extracted skin (purchased from Japan SLC) set in a vertical diffusion cell. 2 mL was put, and 1.77 cm 2 pieces of the adhesive layer of each patch were attached to the donor on the stratum corneum side. Thereafter, 0.6 mL of the receiver solution was collected every predetermined time over 24 hours, and the lidocaine concentration in the receiver solution was measured by the HPLC method. After 0.6 mL was collected, the receiver was supplemented with 0.6 mL of a new 0.05 mol / L McIlvaine buffer. Table 5 shows the cumulative amount of lidocaine permeated for 24 hours, which is the sum of the concentrations of lidocaine measured at each time point.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un timbre transdermique adhésif hydraté qui contient un médicament, présente une excellente ré-adhésion, et dont la séparation de la peau est moins douloureuse. Le timbre transdermique adhésif hydraté est muni d'un corps de support et d'une couche adhésive disposée sur ledit corps de support. La couche adhésive est une préparation d'un médicament, d'eau (pas plus de 30% du poids total de la couche adhésive), et d'alcools polyhydriques (pas plus de 40% du poids total de la couche adhésive). De manière optimale, les alcools polyhydriques contiennent de la glycérine. La couche adhésive contient également une poudre inorganique, et la somme des quantités de ladite poudre inorganique et des alcools polyhydriques constitue de préférence au moins 50% du poids total de la couche adhésive.
PCT/JP2011/056896 2010-03-23 2011-03-23 Timbre transdermique adhésif hydraté WO2011118604A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012507022A JPWO2011118604A1 (ja) 2010-03-23 2011-03-23 含水貼付剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010065573 2010-03-23
JP2010-065573 2010-03-23

Publications (1)

Publication Number Publication Date
WO2011118604A1 true WO2011118604A1 (fr) 2011-09-29

Family

ID=44673155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/056896 WO2011118604A1 (fr) 2010-03-23 2011-03-23 Timbre transdermique adhésif hydraté

Country Status (3)

Country Link
JP (2) JPWO2011118604A1 (fr)
TW (1) TWI506117B (fr)
WO (1) WO2011118604A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176668A1 (fr) * 2011-06-20 2012-12-27 久光製薬株式会社 Cataplasme contenant de la lidocaïne
WO2013027840A1 (fr) * 2011-08-25 2013-02-28 ニプロパッチ株式会社 Patch cutané adhésif hydraté
WO2017073516A1 (fr) * 2015-10-26 2017-05-04 久光製薬株式会社 Timbre cutané adhésif
JP7496621B2 (ja) 2019-04-24 2024-06-07 株式会社 メドレックス リドカイン含有貼付剤

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6099180A (ja) * 1983-11-04 1985-06-03 Lion Corp 水性粘着剤組成物
JPS61172817A (ja) * 1985-01-25 1986-08-04 Sanyo Chem Ind Ltd 医薬部材組成物
JPH04305523A (ja) * 1991-03-30 1992-10-28 Teikoku Seiyaku Co Ltd リドカイン含有外用貼付剤
JPH09268123A (ja) * 1996-03-30 1997-10-14 Nichiban Co Ltd 局所麻酔用貼付剤
JPH10147521A (ja) * 1996-09-18 1998-06-02 Yuutoku Yakuhin Kogyo Kk 持続性疼痛緩和用貼付剤
JP2000007559A (ja) * 1998-06-18 2000-01-11 Ss Pharmaceut Co Ltd 水性粘着膏体
JP2000178186A (ja) * 1998-10-05 2000-06-27 Yuutoku Yakuhin Kogyo Kk 経皮吸収テ―プ剤
JP2004168764A (ja) * 2002-10-30 2004-06-17 Showa Denko Kk 貼付剤用粘着剤組成物およびその製造方法
WO2006090782A1 (fr) * 2005-02-23 2006-08-31 Saitama Daiichi Pharmaceutical Co., Ltd. Composition pour patch adhésif hydraté pour usage externe et patch adhésif comprenant ladite composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3572765B2 (ja) * 1994-12-19 2004-10-06 大正製薬株式会社 パップ剤用膏体
JPH09255565A (ja) * 1996-03-26 1997-09-30 Daikyo Yakuhin Kogyo Kk 皮膚局所麻酔用ヒドロゲルパッチ
JP2003095929A (ja) * 2001-09-27 2003-04-03 Lion Corp 貼付剤
JP2004209074A (ja) * 2003-01-07 2004-07-29 Sanpo Kagaku Kk 皮膚貼付シート及びその製造方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6099180A (ja) * 1983-11-04 1985-06-03 Lion Corp 水性粘着剤組成物
JPS61172817A (ja) * 1985-01-25 1986-08-04 Sanyo Chem Ind Ltd 医薬部材組成物
JPH04305523A (ja) * 1991-03-30 1992-10-28 Teikoku Seiyaku Co Ltd リドカイン含有外用貼付剤
JPH09268123A (ja) * 1996-03-30 1997-10-14 Nichiban Co Ltd 局所麻酔用貼付剤
JPH10147521A (ja) * 1996-09-18 1998-06-02 Yuutoku Yakuhin Kogyo Kk 持続性疼痛緩和用貼付剤
JP2000007559A (ja) * 1998-06-18 2000-01-11 Ss Pharmaceut Co Ltd 水性粘着膏体
JP2000178186A (ja) * 1998-10-05 2000-06-27 Yuutoku Yakuhin Kogyo Kk 経皮吸収テ―プ剤
JP2004168764A (ja) * 2002-10-30 2004-06-17 Showa Denko Kk 貼付剤用粘着剤組成物およびその製造方法
WO2006090782A1 (fr) * 2005-02-23 2006-08-31 Saitama Daiichi Pharmaceutical Co., Ltd. Composition pour patch adhésif hydraté pour usage externe et patch adhésif comprenant ladite composition

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176668A1 (fr) * 2011-06-20 2012-12-27 久光製薬株式会社 Cataplasme contenant de la lidocaïne
JP5512891B2 (ja) * 2011-06-20 2014-06-04 久光製薬株式会社 リドカイン含有パップ剤
US8920831B2 (en) 2011-06-20 2014-12-30 Hisamitsu Pharmaceutical Co., Inc. Lidocaine-containing hydrogel patch
WO2013027840A1 (fr) * 2011-08-25 2013-02-28 ニプロパッチ株式会社 Patch cutané adhésif hydraté
EA026084B1 (ru) * 2011-08-25 2017-02-28 Нипро Пэтч Ко., Лтд. Влагосодержащий адгезивный кожный пластырь
WO2017073516A1 (fr) * 2015-10-26 2017-05-04 久光製薬株式会社 Timbre cutané adhésif
US10441551B2 (en) 2015-10-26 2019-10-15 Hisamitsu Pharmaceutical Co., Inc. Patch
JP7496621B2 (ja) 2019-04-24 2024-06-07 株式会社 メドレックス リドカイン含有貼付剤

Also Published As

Publication number Publication date
JP2016014052A (ja) 2016-01-28
TW201139605A (en) 2011-11-16
JPWO2011118604A1 (ja) 2013-07-04
TWI506117B (zh) 2015-11-01

Similar Documents

Publication Publication Date Title
TW577760B (en) Transdermal patch with non-steroid antirheumatic agents having an acid group
US20080138388A1 (en) Transdermal Absorption Patch
EP1992363B1 (fr) Preparation pour absorption transdermique
JP6142379B2 (ja) 含水貼付剤
JP2003137773A (ja) 積層支持体を有する貼付剤
US9700522B2 (en) Transdermal patch and method for delivery of vitamin B12
JP2016014052A (ja) 含水貼付剤
ES2526440T3 (es) Parche adhesivo menos irritante para la piel
EP3527205B1 (fr) Patch adhésif à base d'eau
EP2865377B1 (fr) Agent favorisant l'absorption percutanée et patch cutané en contenant
KR20210065931A (ko) 함수계 첩부제
JP4764337B2 (ja) 消炎鎮痛貼付剤
CA2941446C (fr) Preparation de piece comprenant un support en couche
EP3040068B1 (fr) Feuille adhésive à appliquer sur la peau, et préparation d'absorption percutanée l'utilisant
EP3988172A1 (fr) Timbre adhésif à base d'eau
ES2385737T3 (es) Fármaco para uso externo y parche adhesivo
JP5181320B2 (ja) 皮膚刺激の少ない経皮吸収型製剤
JP6729584B2 (ja) 経皮吸収型貼付剤
WO2014068600A1 (fr) Système transdermique stable d'administration de médicaments comprenant du diclofénac
JP6695571B2 (ja) 経皮吸収型製剤
JP6512905B2 (ja) フェンタニル含有貼付剤
JP7219177B2 (ja) 非水系貼付剤
JP5878715B2 (ja) 貼付剤
TWI745577B (zh) 經皮吸收製劑
JP2022131753A (ja) 非水系貼付剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11759409

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012507022

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11759409

Country of ref document: EP

Kind code of ref document: A1